You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1376 Results
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Zolbetuximab - First-line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
zolbetuximab,
CISplatin,
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Zolbetuximab - First-line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
zolbetuximab,
CARBOplatin,
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
New Drug Funding Program
    Zolbetuximab - First-line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
zolbetuximab,
CISplatin,
capecitabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
New Drug Funding Program
    Zolbetuximab - First-line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
zolbetuximab,
CARBOplatin,
capecitabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025
The Canada Post service disruption may affect the delivery of cancer screening letters and fecal immunochemical test (FIT) kits for colorectal...
Our Comprehensive Cancer Biomarker Testing Program supports patient management through the testing of diagnostic, predictive and prognostic markers....
Drug
Other Name(s): Truqap™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Updated
Oct 2025
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    capivasertib - For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, based on criteria
ODB - General Benefit
    fulvestrant
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
capivasertib,
fulvestrant
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025

Pages